

Table S1 The specific information for the primary antibodies

Primary antibodies	Details
LAIR1	1:1,000, 67220-1-Ig, China
GAPDH	1:5,000, 10494-1-AP, China
Snail1	ImmunoWay, USA
N-cadherin	ImmunoWay, USA
E-cadherin	ImmunoWay, USA
Ki-67	Zhongshan Golden Bridge, China

GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LAIR1, leukocyte-associated immunoglobulin-like receptor 1.

Table S2 Primer sequences used in qRT-PCR assays

Gene	Primer sequences (5'-3')
<i>LAIR1</i>	Forward: TGGTCTGAGCAGAGTGACTACC
	Reverse: GCTCATTGTGACTGTTGTCCGAC
GAPDH	Forward: CACCCACTCCTCCACCTTTG
	Reverse: CCACCACCCTGTTGCTGTAG

GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; qRT-PCR, quantitative real-time polymerase chain reaction.

Table S3 Sequences of primers for LAIR1 overexpression and knockdown

ID	Target sequences
LAIR1 (26590-1)-P1	AGGTCGACTCTAGAGGATCCCGCCACCATGTCTCCCCACCCACCGC
LAIR1 (26590-1)-P2	TCCTTGAGTCCATACCGTGTCTGGCAACGGCTGCATACG
LAIR1-RNAi (104984-2)	GACCTGGCTGTTGATGTTCTA
LAIR1-RNAi (104985-2)	CCGTCGGACAACAGTCACAAT

LAIR1, leukocyte-associated immunoglobulin-like receptor 1.

Table S4 PanCanSurvPlot database analysis of the relationship between LAIR1 expression and GC prognosis

Gene symbol	Dataset	Platform	Treatment	Survival	KM results with optimal cutpoint		
					HR	95% CI	P value
LAIR1	GSE26253	GPL8432	Chemotherapy + radiotherapy	RFS	0.791	0.547–1.146	1.83e–01
LAIR1	GSE84426	GPL6947	Surgery	OS	0.208	0.019–2.336	3.53e–03
LAIR1	TCGA-STAD	IlluminaHiSeq	Chemotherapy/targeted therapy	PFI	2.89	1.094–7.634	1.28e–03
LAIR1	TCGA-STAD	IlluminaHiSeqV1	Chemotherapy/targeted therapy	DFI	2.24	1.028–4.899	3.3e–03
LAIR1	TCGA-STAD	IlluminaHiSeqV1	Chemotherapy/targeted therapy	DSS	2.13	0.901–5.042	1.52e–02
LAIR1	TCGA-STAD	IlluminaGA	Chemotherapy/targeted therapy	OS	5.55	0.502–61.422	4.26e–03
LAIR1	TCGA-STAD	IlluminaHiSeqV1	Chemotherapy/targeted therapy	OS	1.6	0.818–3.132	8.93e–02
LAIR1	TCGA-STAD	IlluminaHiSeqV1	Chemotherapy/targeted therapy	PFI	2.83	0.971–8.259	3.36e–03
LAIR1	TCGA-STAD	IlluminaHiSeq	Chemotherapy/targeted therapy	DSS	2.39	1.004–5.69	3.41e–03
LAIR1	TCGA-STAD	IlluminaHiSeq	Chemotherapy/targeted therapy	OS	1.9	1.002–3.604	8.64e–03
LAIR1	TCGA-STAD	IlluminaHiSeq	Chemotherapy/targeted therapy	DFI	2.47	1.154–5.301	4.26e–04

CI, confidence interval; DFI, disease-free interval; DSS, disease-specific survival; GC, gastric cancer; HR, hazard ratio; KM, Kaplan-Meier; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; OS, overall survival; PFI, progression-free interval; RFS, relapse-free survival; STAD, stomach adenocarcinoma; TCGA, The Cancer Genome Atlas.




Figure S2 LAIR1 expression profiling and optimal cutoff determination in tumor and normal tissues. (A) IHC scores for LAIR1 staining in the study cohort. (B) Frequency distribution of LAIR1 IHC scores across the cohort. (C) LAIR1 mRNA expression in the 16 paired tissues. (D) X-tile analysis for identifying the optimal cutoff value. **, $P < 0.01$; ****, $P < 0.0001$. IHC, immunohistochemistry; LAIR1, leukocyte-associated immunoglobulin-like receptor 1; mRNA, messenger RNA.